BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Srinivas AN, Suresh D, Santhekadur PK, Suvarna D, Kumar DP. Extracellular Vesicles as Inflammatory Drivers in NAFLD. Front Immunol 2020;11:627424. [PMID: 33603757 DOI: 10.3389/fimmu.2020.627424] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 5.0] [Reference Citation Analysis]
Number Citing Articles
1 Wen L, Li M, Lin X, Li Y, Song H, Chen H. AgNPs Aggravated Hepatic Steatosis, Inflammation, Oxidative Stress, and Epigenetic Changes in Mice With NAFLD Induced by HFD. Front Bioeng Biotechnol 2022;10:912178. [DOI: 10.3389/fbioe.2022.912178] [Reference Citation Analysis]
2 Wu D, Zhu H, Wang H. Extracellular Vesicles in Non-alcoholic Fatty Liver Disease and Alcoholic Liver Disease. Front Physiol 2021;12:707429. [PMID: 34335310 DOI: 10.3389/fphys.2021.707429] [Reference Citation Analysis]
3 Schöler D, Castoldi M, Jördens MS, Schulze-Hagen M, Kuhl C, Keitel V, Luedde T, Roderburg C, Loosen SH. Enlarged extracellular vesicles are a negative prognostic factor in patients undergoing TACE for primary or secondary liver cancer-a case series. PLoS One 2021;16:e0255983. [PMID: 34407090 DOI: 10.1371/journal.pone.0255983] [Reference Citation Analysis]
4 Santos-laso A, Gutiérrez-larrañaga M, Alonso-peña M, Medina JM, Iruzubieta P, Arias-loste MT, López-hoyos M, Crespo J. Pathophysiological Mechanisms in Non-Alcoholic Fatty Liver Disease: From Drivers to Targets. Biomedicines 2022;10:46. [DOI: 10.3390/biomedicines10010046] [Reference Citation Analysis]
5 López-Pastor AR, Infante-Menéndez J, González-Illanes T, González-López P, González-Rodríguez Á, García-Monzón C, Vega de Céniga M, Esparza L, Gómez-Hernández A, Escribano Ó. Concerted regulation of non-alcoholic fatty liver disease progression by microRNAs in apolipoprotein E-deficient mice. Dis Model Mech 2021;14:dmm049173. [PMID: 34850865 DOI: 10.1242/dmm.049173] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Blandin A, Le Lay S. [Extracellular vesicles and metabolic diseases: Dangerous liaisons]. Med Sci (Paris) 2021;37:1125-32. [PMID: 34928216 DOI: 10.1051/medsci/2021209] [Reference Citation Analysis]
7 Gallego-Durán R, Montero-Vallejo R, Maya-Miles D, Lucena A, Martin F, Ampuero J, Romero-Gómez M. Analysis of Common Pathways and Markers From Non-Alcoholic Fatty Liver Disease to Immune-Mediated Diseases. Front Immunol 2021;12:667354. [PMID: 34899679 DOI: 10.3389/fimmu.2021.667354] [Reference Citation Analysis]
8 Li L, Xia Y, Ji X, Wang H, Zhang Z, Lu P, Ding Q, Wang D, Liu M. MIG/CXCL9 exacerbates the progression of metabolic-associated fatty liver disease by disrupting Treg/Th17 balance. Exp Cell Res 2021;407:112801. [PMID: 34461107 DOI: 10.1016/j.yexcr.2021.112801] [Reference Citation Analysis]
9 Newman LA, Muller K, Rowland A. Circulating cell-specific extracellular vesicles as biomarkers for the diagnosis and monitoring of chronic liver diseases. Cell Mol Life Sci 2022;79. [DOI: 10.1007/s00018-022-04256-8] [Reference Citation Analysis]
10 Dragon-Durey MA, Chen X, Kirilovsky A, Ben Hamouda N, El Sissy C, Russick J, Charpentier E, Binois Y, Marliot F, Meylan M, Granier C, Pere H, Saldmann A, Rance B, Jannot AS, Baron S, Chebbi M, Fayol A, Josseaume N, Rives-Lange C, Tharaux PL, Cholley B, Diehl JL, Arlet JB, Azizi M, Karras A, Czernichow S, Smadja DM, Hulot JS, Cremer I, Tartour E, Mousseaux E, Pagès F. Differential association between inflammatory cytokines and multiorgan dysfunction in COVID-19 patients with obesity. PLoS One 2021;16:e0252026. [PMID: 34038475 DOI: 10.1371/journal.pone.0252026] [Reference Citation Analysis]
11 Kemas AM, Youhanna S, Lauschke VM. Non-alcoholic fatty liver disease - opportunities for personalized treatment and drug development. Expert Review of Precision Medicine and Drug Development 2022;7:39-49. [DOI: 10.1080/23808993.2022.2053285] [Reference Citation Analysis]
12 Albhaisi S, Noureddin M. Current and Potential Therapies Targeting Inflammation in NASH. Front Endocrinol (Lausanne) 2021;12:767314. [PMID: 34925237 DOI: 10.3389/fendo.2021.767314] [Reference Citation Analysis]
13 Acharya P, Chouhan K, Weiskirchen S, Weiskirchen R. Cellular Mechanisms of Liver Fibrosis. Front Pharmacol 2021;12:671640. [PMID: 34025430 DOI: 10.3389/fphar.2021.671640] [Reference Citation Analysis]
14 Camps J, Castañé H, Rodríguez-Tomàs E, Baiges-Gaya G, Hernández-Aguilera A, Arenas M, Iftimie S, Joven J. On the Role of Paraoxonase-1 and Chemokine Ligand 2 (C-C motif) in Metabolic Alterations Linked to Inflammation and Disease. A 2021 Update. Biomolecules 2021;11:971. [PMID: 34356595 DOI: 10.3390/biom11070971] [Reference Citation Analysis]